sever
human
monoclon
antibodi
hmab
includ
exhibit
rel
potent
broad
neutral
activ
howev
elicit
vivo
vaccin
immunogen
base
envelop
glycoprotein
env
success
hypothes
evolv
strategi
reduc
elimin
immunogen
highli
conserv
epitop
antibodi
use
hole
absenc
weak
bind
epitop
germlin
antibodi
suffici
initi
andor
maintain
effici
immun
respons
human
germlin
b
cell
receptor
bcr
repertoir
begin
test
hypothesi
design
germlinelik
antibodi
correspond
close
well
crossreact
rel
weak
neutral
activ
nativ
occur
antibodi
due
size
andor
effect
germlinelik
bound
rel
high
affin
test
env
contrast
germlinelik
lack
measur
bind
env
elisa
assay
although
correspond
matur
antibodi
result
provid
initi
evid
env
structur
contain
conserv
vulner
epitop
may
initi
humor
respons
bind
germlin
antibodi
even
respons
initi
weak
bind
undetect
assay
like
outcompet
respons
structur
contain
epitop
antibodi
bind
germlin
bcr
much
higher
affinityavid
hypothesi
support
data
could
contribut
understand
evad
immun
respons
offer
new
concept
design
effect
vaccin
immunogen
potent
broadli
crossreact
neutral
antibodi
bnab
rel
rare
found
patient
infect
possibl
caus
includ
protect
conserv
structur
viru
envelop
glycoprotein
env
variabl
loop
extens
glycosyl
occlus
within
oligom
conform
mask
well
rapid
gener
mutant
outpac
develop
antibodi
immunoregulatori
mechan
env
immunogen
number
envspecif
hmab
identifi
howev
sever
hmab
includ
igg
igg
igg
extens
character
found
exhibit
rel
potent
broad
neutral
activ
isol
differ
clade
exist
antibodi
fuel
hope
develop
efficaci
hiv
vaccin
achiev
provid
immunogen
contain
epitop
antibodi
appropri
design
howev
spite
larg
amount
research
antibodybas
vaccin
capabl
elicit
broadli
neutral
antibodi
achiev
inabl
achiev
elicit
bnab
human
indic
still
unknown
fundament
immunolog
mechan
allow
hiv
evad
elicit
bnab
understand
mechan
could
provid
novel
tool
develop
efficaci
vaccin
earli
studi
found
rel
extens
antigendriven
matur
nonrestrict
use
v
gene
sever
hivspecif
antibodi
later
analysi
nonneutr
hiv
human
antibodi
show
averag
mutat
frequenc
approxim
recent
studi
gene
usag
extent
matur
antibodi
suggest
restrict
gene
usag
antibodi
long
antibodi
short
note
studi
two
best
character
bnab
nearli
higher
somat
hypermut
mutat
frequenc
antibodi
analyz
studi
tabl
hypothes
high
diverg
known
bnab
correspond
germlin
antibodi
may
indic
germlin
antibodi
lack
capabl
bind
epitop
matur
antibodi
design
germlinelik
antibodi
correspond
well
sever
human
hmab
fab
potent
bnab
fullsiz
antibodi
exhibit
averag
significantli
decreas
potenc
like
due
sizerestrict
access
epitop
crossreact
neutral
hmab
rel
modest
potenc
found
germlinelik
bind
env
although
correspond
matur
antibodi
bind
rel
high
level
activ
contrast
germlinelik
bound
rel
high
affin
test
env
result
provid
initi
evid
germlinelik
antibodi
correspond
known
bnab
antibodi
may
capabl
bind
env
initi
andor
maintain
immun
respons
lead
elicit
vivo
bal
provid
tim
fout
univers
maryland
baltimor
md
recombin
protein
provid
christoph
broder
usuh
bethesda
md
heavi
light
chain
nucleotid
sequenc
analyz
mab
v
j
align
assign
germlin
gene
yield
fewest
nucleotid
mismatch
valu
p
use
compar
segment
align
expect
random
chanc
minimum
requir
segment
align
depend
length
v
j
region
match
nucleotid
least
addit
match
everi
mismatch
germlinelik
sequenc
determin
revert
mutat
germlin
sequenc
retain
origin
junction
termin
deoxynucleotidyl
transferas
tdt
n
nucleotid
scfv
dna
correspond
matur
germlinelik
synthes
genescript
genescript
piscatawi
nj
accuraci
confirm
sequenc
vh
antibodi
follow
gggg
linker
vl
sfii
restrict
site
ad
n
c
termini
scfv
gene
synthesi
clone
plasmid
provid
denni
burton
scripp
institut
la
jolla
cal
express
bacteria
vector
add
tag
c
terminu
insert
scfv
tag
use
subsequ
scfv
purif
detect
elisa
dna
fragment
encod
select
scfv
antibodi
fuse
fc
human
clone
mammalian
cell
express
vector
invitrogen
carlsbad
ca
express
fusion
protein
scfv
express
ecoli
strain
transform
scfv
construct
describ
singl
clone
inocul
supplement
unit
ampicillin
glucos
incub
shake
reach
iptg
ad
achiev
final
concentr
mm
cultur
continu
overnight
shake
cell
collect
lyse
polymyxin
b
sigma
st
loui
pb
supernat
subject
ninta
agaros
bead
qiagen
hilden
germani
purif
solubl
scfv
scfvfc
construct
transfect
freestyl
cell
polyfectin
transfect
agent
invitrogen
four
day
transfect
cultur
medium
collect
secret
scfvfc
protein
purifi
use
proteina
sepharos
column
ge
healthcar
piscataway
nj
protein
antigen
dilut
pb
buffer
concentr
rang
ad
well
plate
left
overnight
coat
plate
plate
block
pb
dri
milk
buffer
scfv
scfvfc
differ
concentr
dilut
block
buffer
appli
elisa
plate
mouseantihishrp
use
detect
tag
c
terminu
end
scfv
clone
mouseantihuman
fchrp
use
detect
fc
tag
scfvfc
elisa
unless
indic
otherwis
hrp
substrat
abt
roch
mannheim
germani
ad
well
od
taken
minut
afterward
identifi
character
number
hmab
exhibit
crossreact
neutral
activ
primari
isol
differ
clade
well
number
hmab
sar
cov
hendra
nipah
virus
one
antibodi
potent
neutral
sar
cov
isol
human
anim
other
henipavirus
nipah
hendra
identif
mani
hmab
variou
infecti
agent
provid
opportun
analyz
compar
antibodi
sequenc
identifi
closest
germlin
ig
gene
calcul
antibodi
gene
diverg
number
amino
acid
chang
correspond
germlin
antibodi
use
mostli
vh
gene
comparison
found
antibodi
three
bnab
publicli
avail
dna
sequenc
hypermut
normal
donor
memori
b
cell
averag
mutat
per
vh
sequenc
tabl
data
shown
contrast
antibodi
sar
cov
henipavirus
includ
sever
mutat
closest
germlin
averag
data
shown
potent
antibodi
bacteri
pathogen
yersinia
pesti
also
rel
low
number
mutat
xiao
x
et
al
unpublish
result
indic
bnab
significantli
diverg
closest
germlin
antibodi
hmab
sar
cov
henipavirus
potent
broad
neutral
activ
test
whether
closest
germlinelik
antibodi
presum
initi
hypermut
process
bind
env
design
correspond
germlinelik
antibodi
tabl
divers
segment
heavi
chain
germlin
sequenc
could
determin
confid
origin
segment
amino
acid
sequenc
use
synthes
germlinelik
ab
explor
hypothesi
germlin
antibodi
conserv
epitop
may
bind
structur
contain
epitop
correspond
matur
antibodi
synthes
gene
six
germlinelik
antibodi
scfv
format
purifi
scfv
test
bind
elisa
assay
recombin
env
use
target
antigen
observ
high
affin
bind
germlinelik
lower
affin
bind
germlinelik
antibodi
fig
contrast
measur
bind
germlinelik
antibodi
even
high
rang
concentr
elisa
signal
neg
control
irrelev
antigen
fig
result
demonstr
germlinelik
antibodi
correspond
three
antibodi
bind
recombin
elisa
assay
even
high
concentr
test
whether
avid
effect
could
lead
measur
bind
germlinelik
construct
express
purifi
bival
scfvfc
fusion
protein
antibodi
exhibit
measur
bind
elisa
assay
even
high
rang
concentr
fig
expect
due
avid
effect
bind
fc
fusion
protein
germlinelik
enhanc
fig
result
indic
bival
avid
effect
lead
measur
bind
germlinelik
elisa
assay
other
found
number
neutral
antibodi
unusu
high
frequenc
somat
hypermut
increas
somat
hypermut
associ
increas
nonsynonym
amino
acid
substitut
contrast
neutral
hmab
sever
virus
caus
acut
infect
contain
fewer
amino
acid
substitut
notabl
potent
bnab
sar
cov
henipavirus
select
screen
larg
nonimmun
antibodi
librari
deriv
ten
healthi
volunt
respect
env
method
resembl
certain
extent
vivo
immun
mimic
better
b
cell
respond
primari
immun
heavi
chain
antibodi
librari
normal
donor
type
correspond
igm
b
cell
librari
screen
methodolog
use
env
weakli
neutral
noncrossreact
antibodi
result
data
shown
pan
anoth
igm
librari
larg
number
healthi
individu
result
nonneutr
even
infectionenhanc
antibodi
chen
et
al
submit
previou
attempt
select
hivspecif
antibodi
nonimmun
librari
also
result
antibodi
modest
neutral
activ
limit
breadth
neutral
result
indic
develop
strategi
protect
highli
conserv
epitop
initi
immun
respons
contrast
sar
cov
henipavirus
appear
lack
mechan
env
contain
expos
conserv
receptor
bind
site
bind
igm
b
cell
suffici
affin
induc
class
switch
affin
matur
therefor
unlik
envbas
vaccin
immunogen
particular
receptor
bind
domain
sar
cov
henipavirus
highli
effect
elicit
bnab
support
line
reason
find
germlinelik
lack
measur
bind
env
detect
bind
rel
high
antibodi
concentr
although
gener
threshold
b
cell
activ
believ
order
equilibrium
dissoci
constant
demonstr
even
lower
affinityavid
interact
trigger
b
cell
activ
mice
howev
even
bind
occur
low
avid
activ
b
cell
express
bcr
like
outcompet
b
cell
express
bcr
bind
epitop
higher
affin
avid
epitop
includ
repres
epitop
repres
epitop
antibodi
target
highli
conserv
immunogen
structur
overlap
coreceptor
bind
site
antibodi
abund
patient
infect
demonstr
differ
respons
high
low
affin
b
cell
rel
small
competit
experi
highaffin
b
cell
respond
antigen
one
hypothes
lengthi
chronic
infect
hiv
evolv
mechan
protect
vulner
function
import
conserv
structur
includ
bind
site
conserv
carbohydr
membran
proxim
extern
region
mper
use
hole
human
germlin
bcr
repertoir
ie
structur
bind
bind
weakli
germlin
antibodi
time
hiv
evolv
structur
either
access
fullsiz
antibodi
eg
epitop
includ
one
function
import
bind
rel
high
affin
b
cell
express
germlin
antibodi
outcompet
b
cell
express
bcr
conserv
epitop
conclus
result
indic
anoth
possibl
mechan
use
evad
neutral
immun
respons
may
abl
protect
vulner
expos
conserv
epitop
use
hole
human
germlin
repertoir
germlin
bcr
recogn
epitop
initi
andor
maintain
immun
respons
compet
bcr
bind
nonessenti
nonaccess
epitop
high
affin
may
miss
repertoir
would
like
emphas
studi
initi
attempt
explor
possibl
mechan
much
work
need
prove
use
knowledg
gain
design
effect
vaccin
immunogen
capabl
elicit
potent
bnab
detect
bind
germlinelik
antibodi
scfv
format
env
bal
fusion
protein
coat
well
elisa
plate
detect
scfv
bind
wherea
coat
detect
scfv
bind
indic
concentr
matur
germlinelik
antibodi
compar
lack
bind
germlinelik
antibodi
scfv
format
bal
coat
detect
bind
coat
detect
bind
scfv
matur
germlinelik
format
compar
lack
bind
germlinelik
antibodi
fc
fusion
protein
format
env
bal
coat
detect
matur
germlinelik
scfvfc
bind
coat
detect
bind
matur
scfv
germlinelik
scfvfc
detect
bind
germlinelik
antibodi
fc
fusion
protein
format
env
env
coat
detect
bind
scfvfc
fusion
protein
tabl
germlinelik
v
j
gene
usag
sequenc
variabl
gene
mutat
best
align
probabl
match
random
match
b
best
segment
align
invert
r
germlin
gene
c
individu
gene
could
identifi
